ESR1 and breast carcinoma: However, contrarily to NGB, the GOBO analysis did not show any significant correlation between MB expression and Relapse-Free Survival (RFS) outcomes in the G1, G2, and G3 subgroups of the ERα+ breast cancer data set (available at http://co.bmc.lu.se/gobo.